HPRA-licensed supplier · MCAP-listed since November 2021

Cannabis-based medicinal products, supplied to Irish patients under the Medical Cannabis Access Programme.

Oleo Technologies supplies pharmaceutical-grade Bedrocan cannabis-based medicinal products to MCAP-registered prescribers and Section 56 dispensing pharmacies across Ireland. Founded 2019. Bedrocan import licence granted 2021. CRO 651282.

Healthcare professional

I am an MCAP-registered prescriber or Section 56 pharmacist.

Access the prescriber portal for product information, batch availability, Certificates of Analysis, and direct supply ordering. Verification required.

Enter prescriber portal Patient or family member

I am asking about access to medical cannabis in Ireland.

Read about the Medical Cannabis Access Programme, eligible conditions under the Misuse of Drugs (Amendment) Regulations 2017, and the prescribing pathway via your healthcare professional.

Read about MCAP

HPRA listingMCAP supplier · Nov 2021

CRO651282

Registered officeBallygarvan, Cork

FoundedFebruary 2019

Supply partnerBedrocan International BV

Programme eligibility

Three conditions defined under MCAP.

The Medical Cannabis Access Programme was established under the Misuse of Drugs (Amendment) Regulations 2017. Eligibility is condition-specific and statutorily defined. Cannabis-based medicinal products under MCAP can only be prescribed by a consultant for a patient who has not responded to standard treatments.

Speak to your healthcare professional. The prescribing pathway begins with a consultant referral; Oleo supplies the medicine through Section 56 dispensing pharmacies once a valid private prescription is in place.

Severe drug-resistant epilepsy. Where standard antiepileptic treatments have not produced adequate seizure control.

MDR 2017

Multiple sclerosis spasticity. Spasticity associated with multiple sclerosis unresponsive to standard treatment.

MDR 2017

Intractable nausea and vomiting from chemotherapy. Where conventional antiemetics have not provided adequate control.

MDR 2017

Misuse of Drugs (Amendment) Regulations 2017 (S.I. No. 262 of 2017). Programme administered by the Health Products Regulatory Authority. Eligibility determined by the prescribing consultant.

Supply chain

A three-year regulatory grind to bring Bedrocan to Ireland.

Bedrocan is the only producer of standardised, pharmaceutical-grade cannabis flos that meets European pharmacopoeia standards for medicinal use.

Import licence

Granted by HPRA in November 2021 after a three-year regulatory and compliance process. Renewable annually under the Misuse of Drugs (Amendment) Regulations 2017.

GMP standard

Bedrocan products are produced under European Good Manufacturing Practice. Each batch ships with a full Certificate of Analysis covering cannabinoid content, terpene profile, microbial screen, heavy metals, and pesticide residue.

Cold chain

Temperature-controlled supply from Bedrocan's Veendam facility to Section 56 pharmacies in Ireland. 5 to 7 working day standard order lead time.

Schedule 1 handling

All product is handled as Schedule 1 controlled drug at every point in the supply chain. CDR/3 record maintained per Misuse of Drugs (Amendment) Regulations 2017.

Clinical pharmacy bench with controlled-drug record book and dispensing materials

Section 56 dispensing pharmacy. Cork, Ireland.

OleoCare patient app

A clinical-grade companion for enrolled MCAP patients.

OleoCare is the patient app for those already enrolled in MCAP and on a valid prescription. It is not a marketing app and is not available to the general public. Patients access it through their prescriber after enrolment.

Daily symptom tracking

Patients log symptoms on a 0 to 10 scale across the conditions their prescriber is monitoring. The data is theirs. It is shared with the prescribing clinician at the patient's discretion.

Dose reminders, prescriber-set

Reminders are configured by the prescriber, not the patient. Adjusting dose without prescriber consultation is not supported in the app.

iii

Article 9 GDPR compliant

Special-category health data handled under Article 9 of GDPR. Data Protection Impact Assessment on file. No third-party tracking or advertising SDKs.

Prescriber dashboard

Prescribing clinicians see longitudinal symptom data for the patients they have added. The clinical relationship is preserved; the supplier is the supply backbone.

Profile

Daily log

Panacea vaporiser device, clinical product photography

Panacea vaporiser

Pharmacopoeia-aligned delivery, designed for MCAP patients.

The Panacea vaporiser is the delivery device commissioned by Oleo for prescribed MCAP patients. Convection-based heating, controlled temperature ranges, no combustion. Designed to align with the European Pharmacopoeia 2.9.18 inhalation monograph.

Heating method

Convection, no combustion

Temperature range

160 - 220 degrees C, prescriber-set defaults

Session timing

Defined inhalation sessions, app-tracked

Warranty

2-year clinical warranty

Regulatory class

MDR classification under review

The Panacea device is supplied to enrolled MCAP patients under the supervision of their prescribing clinician. Dose, frequency, and duration are clinician-defined.

Richard Creagh, Co-Founder.

Founder note

A founder team built for the regulated pharmaceutical supply chain, not for marketing.

The job here is to be a quietly dependable backbone. Patients have a clinical relationship with their prescriber. Our role is to make sure the medicine is on the pharmacy shelf when the prescription arrives.

Oleo Technologies was co-founded in February 2019 by Richard Creagh and Shirley Creagh. Richard spent 25 years in medtech sales, including five years at Applied Medical, where he was promoted to National Sales Manager and launched the Advanced Energy Devices line. Shirley is co-founder and Chief Technology Officer; her background spans technology operations and regulated systems.

The Bedrocan import licence took three years of regulatory and compliance work to land. That sequence, the medtech background and the regulatory grind, is the spine of how Oleo operates today.

Education

Computer Science, Munster Technological University, 1997-2002

Prior roles

Applied Medical (National Sales Manager), Asensus Surgical, Creco Trading

Co-founder

Shirley Creagh, Co-Founder and CTO

Regulatory framework

The full set of frameworks Oleo operates under.

Stated in plain regulatory English, sourced from the legislation. No marketing language.

MDR 2017

Misuse of Drugs (Amendment) Regulations 2017

S.I. No. 262 of 2017. Establishes the Medical Cannabis Access Programme, the eligible conditions, the prescribing requirements, and the supply chain for cannabis-based medicinal products in Ireland.

HPRA

Health Products Regulatory Authority oversight

Oleo is an HPRA-listed MCAP supplier since November 2021. Annual licence renewal, batch documentation, and pharmacovigilance reporting under HPRA prescribing guidance.

ASAI 7th ed.

Advertising Standards Authority of Ireland

The 7th edition Code prohibits direct-to-public advertising of prescription-only medicines. Product-specific information sits behind the prescriber portal gate. Public pages describe the company and the programme only.

MPCM 2007

Medicinal Products (Control of Manufacture) Regulations 2007

Good Manufacturing Practice (GMP) supply requirements. Bedrocan is supplied to Oleo under European GMP; documentation accompanies every batch.

Schedule 1 CD

Misuse of Drugs (Amendment) Act, Schedule 1

Storage, dispensing, record-keeping, and disposal at pharmacy level. CDR/3 register required at every Section 56 dispensing pharmacy handling Bedrocan.

GDPR Art. 9

GDPR special-category health data

OleoCare patient app handles Article 9 special-category data. Data Protection Impact Assessment on file with the Data Protection Commission. No third-party tracking SDKs.

Healthcare professionals

Request a prescriber pack.

One-page MCAP enrolment summary, current product list with batch availability, and a direct line to clinical and regulatory support. Verification required.

Enter the prescriber portal

Patients and families

Speak to your healthcare professional.

The prescribing pathway begins with a consultant referral. We do not provide medical advice and do not communicate with patients outside the OleoCare app, which is enrolled-patients-only.

Read the patient guide to MCAP